Health and Healthcare Systems

New study shows impact of boosters on protection against Omicron

Booster vaccination program for the general public amid the rise of the Omicron variant in Jakarta.

The research showed greated protection after 3 doses of a COVID-19 vaccine. Image: REUTERS/Willy Kurniawan

MGH News and Public Affairs
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how COVID-19 is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:


This article is part of: Centre for Health and Healthcare
  • Traditional regimens of COVID-19 vaccines do not neutralize the fast-spreading Omicron variant according to an MGH, MIT, and Harvard study.
  • Individuals who received three doses of the mRNA vaccine had very significant neutralization against the Omicron variant, as opposed to those with two doses.

An additional “booster” dose of Moderna or Pfizer mRNA-based vaccine is needed to provide immunity against the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, according to a study by researchers at the Ragon Institute of MGH, MIT and Harvard. The results of this study, reported in the journal Cell, indicate that traditional dosing regimens of COVID-19 vaccines available in the United States do not produce antibodies capable of recognizing and neutralizing the Omicron variant.

In late November, health officials in South Africa reported that a previously unknown variant of SARS-CoV-2 was rapidly spreading throughout the country. The variant, given the name Omicron by the World Health Organization, would soon prove to be far more transmissible than Delta, the variant that previously had caused the majority of COVID-19 infections. “People desperately wanted to know whether current vaccines protect against Omicron,” says the senior author of the Cell paper, Alejandro Balazs, whose laboratory at the Ragon Institute investigates how to engineer immunity against infectious diseases.

To find answers, Balazs collaborated with a team that included the lead author of the Cell paper, Wilfredo F. Garcia-Beltran, a clinical pathology resident at MGH and a clinician-scientist fellow at the Ragon Institute. The first step was to construct a harmless version of Omicron known as a “pseudovirus” that could be used in the laboratory to evaluate the effectiveness of the three COVID-19 vaccines available in the United States, which include the two-dose Pfizer and Moderna injections and the one-dose Johnson & Johnson vaccine. The pseudovirus that Balazs and colleagues created mimicked the behavior of Omicron, which has 34 mutations on its “spike” protein that are not found on the original strain of SARS-Cov-2 first detected in Wuhan, China, in December 2019. Scientists believe that these mutations may be partially responsible for Omicron’s rapid spread throughout the world.

Next, Garcia-Beltran worked with colleagues at MGH, including hematology-oncology fellow Vivek Naranbhai, to acquire blood samples from 239 individuals who had been fully vaccinated with one of the three COVID-19 vaccines. The study subjects included employees within the Massachusetts General Brigham health care system and residents of Chelsea, Massachusetts, a community with a high rate of COVID-19 infections. “It was important to us to have a diverse population represented in the study,” says Garcia-Beltran. Included in this group were 70 men and women who had received a third booster dose of either the Pfizer or Moderna vaccine, according to recommendations by the Centers for Disease Control and Prevention.

COVID-19 booster doses per capita in selected countries.
COVID-19 booster doses per capita in selected countries. Image: Our World in Data
Have you read?

The blood samples were used to measure how effectively each vaccine induces production of protective immunity in the form of antibodies against the Omicron pseudovirus, as well as the Delta and wild type viruses. The results were striking. “We detected very little neutralization of the Omicron variant pseudovirus when we used samples taken from people who were recently vaccinated with two doses of mRNA vaccine or one dose of Johnson & Johnson,” says Balazs. “But individuals who received three doses of mRNA vaccine had very significant neutralization against the Omicron variant.”

It’s not yet clear why an mRNA booster dramatically improves immune protection against Omicron, but Garcia-Beltran says one possibility is that an additional dose creates antibodies that bind more tightly to the spike protein, increasing their effectiveness. Also, a booster dose may generate antibodies that target regions of the spike protein that are common to all forms of SARS-CoV-2. Both theories may be true, says Garcia-Beltran.


What is the World Economic Forum doing about access to vaccines?

Balazs notes that the three-dose mRNA vaccine regimen — that is, the traditional two doses and a booster of Pfizer or Moderna vaccines — provides somewhat lower levels of neutralizing antibodies against Omicron than it does against the COVID-19 wild type strain or Delta variant. But the study’s results strongly support the CDC’s advice that COVID-19 booster shots are appropriate for anyone 16 and older, and that mRNA vaccines are preferred.

Balazs is a principal investigator at the Ragon Institute and an assistant professor of Medicine at Harvard Medical School. Garcia-Beltran recently established his own laboratory at the Ragon Institute.

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

How One Health can help ease climate-driven health crises

Shyam Bishen

July 15, 2024

About Us



Partners & Members

  • Sign in
  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum